Search
01/01/2023
Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project
Sánchez E., Sánchez M., López-Cano C., Bermúdez-López M., Valdivielso J.M., Farras-Salles, C, Pamplona R., Torres G., Mauricio D., Castro E., Fernández E., Lecube A.. Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project. Nutrients. 2023; 15(1)DOI:10.3390/nu15010203. PMID:36615860. IF:4.800(Q1/2D).
01/01/2023
Obesity and fertility. Position statement
Miñambres I., de Hollanda A., Vilarrasa N., Pellitero S., Rubio M.A., Flores L., Caixàs A., Lobo S., Martinez Salamanca J.I., Acevedo B., Moizé V., Andreu A., Escalada J.. Obesity and fertility. Position statement. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.10.002. PMID:. IF:(Q/D).
01/01/2023
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología
Pedro-Botet J., Barrios V., Sánchez-Margalet V., Tamargo J., Arrieta F., Gámez J.M., Gimeno-Orna J.A., Escobar C., Gómez-Doblas J.J., Pérez A.. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.03.004. PMID:. IF:(Q/D).
01/01/2023
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial
Mathiesen E.R., Alibegovic A.C., Corcoy R., Dunne F., Feig D.S., Hod M., Jia T., Kalyanam B., Kar S., Kautzky-Willer A., Marchesini C., Rea R.D., Damm P.. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes & Endocrinology. 2023; 11(2)DOI:10.1016/S2213-8587(22)00307-2. PMID:36623517. IF:44.000(Q1/1D).
01/01/2023
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study
Julián M.T., Ballesta S., Pera G., Pérez-Montes de Oca A., Soldevila B., Caballería L., Morillas R., Expósito C., Martínez–Escudé A., Puig-Domingo M., Franch-Nadal J., Torán P., Cusi K., Julve J., Mauricio D., Alonso N.. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. Frontiers in Endocrinology. 2023; 13DOI:10.3389/fendo.2022.1051958. PMID:36714592. IF:3.900(Q2/3D).
01/01/2023
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino T., Alexander C.M., Amiel S.A., Arreaza-Rubin G., Beck R.W., Bergenstal R.M., Buckingham B.A., Carroll J., Ceriello A., Chow E., Choudhary P., Close K., Danne T., Dutta S., Gabbay R., Garg S., Heverly J., Hirsch I.B., Kader T., Kenney J., Kovatchev B., Laffel L., Maahs D., Mathieu C., Mauricio D., Nimri R., Nishimura R., Scharf M., Del Prato S., Renard E., Rosenstock J., Saboo B., Ueki K., Umpierrez G.E., Weinzimer S.A., Phillip M.. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes & Endocrinology. 2023; 11(1)DOI:10.1016/S2213-8587(22)00319-9. PMID:36493795. IF:44.000(Q1/1D).
01/01/2023
Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project
Ampudia-Blasco F.J., Ugarte-Abasolo E., Chico A., García-Alemán J., Galan-Barroso M.. Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project. Journal Of Diabetes Science And Technology. 2023; 17(5)DOI:10.1177/19322968221087270. PMID:35466722. IF:(Q/D).
01/01/2023
Low adherence to the Mediterranean diet is associated with increased prevalence and number of atherosclerotic plaques in the ILERVAS cohort
Rojo-López M.I., Bermúdez-López M., Castro E., Farràs C., Torres G., Pamplona R., Lecube A., Valdivielso J.M., Fernández E., Julve J., Castelblanco E., Franch-Nadal J., Alonso N., Granado-Casas M., Mauricio D., Miquel E., Ortega M., Barbé F., González J., Barril S., Sánchez-de-la-Torre M., Portero-Otín M., Jové M., Hernández M., Rius F., Godoy P., Alonso M.M.. Low adherence to the Mediterranean diet is associated with increased prevalence and number of atherosclerotic plaques in the ILERVAS cohort. ATHEROSCLEROSIS. 2023; 380DOI:10.1016/j.atherosclerosis.2023.117191. PMID:37586219. IF:4.900(Q1/2D).